Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target hoisted by analysts at Roth Capital from $82.00 to $170.00 in a research note issued to investors on Monday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Roth Capital’s target price suggests a potential upside of 108.41% from the company’s current price.

MDGL has been the topic of several other reports. HC Wainwright assumed coverage on Madrigal Pharmaceuticals in a research report on Wednesday, November 29th. They set a “buy” rating and a $54.00 price target on the stock. JMP Securities upped their price target on Madrigal Pharmaceuticals from $40.00 to $63.00 and gave the company an “outperform” rating in a research report on Friday, October 13th. Finally, Evercore ISI upped their price target on Madrigal Pharmaceuticals from $65.00 to $140.00 and gave the company an “outperform” rating in a research report on Thursday. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Madrigal Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $135.00.

Madrigal Pharmaceuticals (NASDAQ MDGL) traded down $0.80 during trading on Monday, hitting $81.57. The stock had a trading volume of 276,600 shares, compared to its average volume of 60,692. Madrigal Pharmaceuticals has a 12 month low of $13.09 and a 12 month high of $101.00.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.79) by $0.11. sell-side analysts anticipate that Madrigal Pharmaceuticals will post -2.57 earnings per share for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the business. VHCP Management II LLC acquired a new stake in Madrigal Pharmaceuticals in the third quarter worth $1,349,000. Shikiar Asset Management Inc. increased its position in Madrigal Pharmaceuticals by 52.8% in the third quarter. Shikiar Asset Management Inc. now owns 23,141 shares of the biopharmaceutical company’s stock worth $1,041,000 after buying an additional 8,000 shares during the period. Victory Capital Management Inc. acquired a new stake in Madrigal Pharmaceuticals in the third quarter worth $2,274,000. Citigroup Inc. acquired a new stake in Madrigal Pharmaceuticals in the second quarter worth $185,000. Finally, New York State Common Retirement Fund acquired a new stake in Madrigal Pharmaceuticals in the second quarter worth $109,000. 21.40% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Madrigal Pharmaceuticals (MDGL) Price Target Raised to $170.00 at Roth Capital” was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/12/11/madrigal-pharmaceuticals-mdgl-price-target-raised-to-170-00-at-roth-capital.html.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).

Receive News & Ratings for Madrigal Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.